BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents
November 08, 2015 at 16:54 PM EST
BIND Therapeutics, Inc. (NASDAQ: BIND) today reported data demonstrating the efficacy and tolerability of BIND's ...